Moderate Hepatic Impairment Clinical Trial
Official title:
An Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Impairment on the Pharmacokinetics of MK-6482
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02871570 -
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
|
Phase 1 | |
| Completed |
NCT05116826 -
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
|
Phase 1 | |
| Completed |
NCT04223635 -
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
|
Early Phase 1 | |
| Completed |
NCT01012284 -
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT05610657 -
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
|
Phase 1 | |
| Completed |
NCT04534699 -
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
|
Phase 1 | |
| Recruiting |
NCT05224609 -
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
|
Phase 1 |